A nationally recognized leader in healthcare fraud and abuse, Howard Young has advised healthcare organizations and life science companies for almost 30 years and brings a solutions-oriented approach to address their complex legal and regulatory needs. Howard has held senior leadership positions in the federal government and in private practice, and currently co-leads the firm’s global healthcare industry team and sits on the Chair’s Advisory Board. Howard counsels on government investigations and audits, litigation, regulatory, and transactional matters.
He is quite simply the dean of the hospice and home health Bar. He knows the industry like an operator, and combines that with 'best in the Bar' legal knowledge.
Healthcare organizations turn to him for compliance and strategic business issues, to handle internal and government investigations, False Claims Act (FCA) qui tam litigation, Department of Health and Human Services (HHS) Office of Inspector General (OIG) inquiries, and government self-disclosures. Howard regularly advises investors, including private equity firms, and providers on transactions, affiliations, and joint ventures.
Howard’s clients include a wide range of providers and suppliers, including hospice and palliative care, home health, long term care, specialty and retail pharmacies, hospitals and academic medical centers, behavioral health providers, physician practices, vision care providers, medical device manufacturers and suppliers, telehealth providers, healthcare vendors, pharmacy benefit managers (PBMs), health plans, and distributors.
As a former senior managing lawyer with the HHS OIG, Howard has experience advising and litigating on OIG and state exclusion matters, and successfully litigated a mandatory exclusion matter in federal court (the only instance when a federal court has reversed an OIG exclusion action). He also assists clients responding to program integrity actions of the Centers of Medicare & Medicaid Services (CMS) contractors, such as the unified program integrity contractors (UPICs) and Supplemental Medical Review Contractor, regarding audits and billing revocation and payment suspensions, as well as OIG audits and investigations. During the COVID-19 public health emergency, Howard advised a wide array of healthcare organizations on federal and state waivers, CARES Act grant issues, OIG audit readiness, and OIG response issues.
Howard frequently writes and presents on fraud and abuse and healthcare regulatory issues to major healthcare trade and professional associations as well as to clients’ executive teams, boards of directors, and sales and marketing personnel.
Advises national, regional and community hospice organizations and industry trade groups on Medicare and Medicaid regulatory matters, transactions, audits, government investigations, and administrative appeals.
Served as lead counsel to various hospice and homecare organizations on federal and state government investigations and audits of hospice eligibility, levels of care (GIP and CHC ), and associated Medicare and Medicaid billing issues. Howard advises on effective subpoena/CID response, coordination with senior management, and managing of clinical experts related to record reviews. Howard also has advised numerous hospices and home healthcare organizations to successfully resolve qui tam FCA complaints and litigation.
Lead counsel for national retail pharmacy in resolving two qui tam complaint investigations related to Medicaid billing issues, resulting in a favorable settlement for a fraction of what the Department of Justice (DOJ) and state government had initially demanded. Also served as counsel to the company on an OIG Corporate Integrity Agreement in connection with multiple additional FCA matters resolved contemporaneously.
Obtained a federal and state government declination and complete dismissal of a qui tam whistleblower complaint in a nationwide investigation of a chain retail pharmacy following complex CID subpoena response related to pharmacy billing and Drug Utilization Review issues.
Advises providers and suppliers, including retail pharmacy chains, regarding potential repayment obligations to Medicare, Medicaid, other government-funded programs and commercial insurers, including potential assessment of FCA liability.
Counsel in FCA litigation for a hospice in federal district court following DOJ intervention in a qui tam lawsuit on allegations related to clinical ineligibility of hospice patients, improper physician billing and improper face-to-face compliance, resulting in highly favorable out of court settlement.
Represented a hospice seller in a complex arbitration proceeding related to sale of a hospice company to a private equity-backed hospice company, including a highly favorable resolution of an OIG self-disclosure related to various hospice compliance issues.
Represents retail and specialty pharmacies on a wide range of state and federal regulatory matters, including board of pharmacy and DEA oversight, Medicare and Medicaid reimbursement matters, exclusion matters, internal investigations and compliance program matters.
Advises several global medical device manufacturers with regard to various fraud and abuse compliance matters, interactions with HCPs, and regulatory due diligence on transactions.
Obtained a declination and complete dismissal of a federal qui tam investigation of a dental management company following an innovative response to a DOJ civil investigative demand.
Represented various post-acute care providers, including skilled nursing facilities, hospices and home health agencies, to resolve qui tam litigation, including intervened and declined qui tam matters.
Represented providers in accountable care organizations (ACOs)–shared savings program and bundled payment arrangements.
Advises digital health companies and medical device manufacturers on innovative programs to improve healthcare delivery through telehealth, remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM), including successful navigation of new Medicare coverage for RPM and RTM.
Advises national and regional retailers and online retailers regarding new consumer-oriented healthcare delivery models.
Advising private equity investors in the pain management, home health, hospice, pharmacy, vision care, wound care, sleep lab, outpatient services, urgent care clinic and telehealth sectors.
Served as lead counsel in the successful representation of two hospitals in a large healthcare system to settle a qui tam investigation for considerably less than the government was seeking, and with no CIA, of Medicare inpatient short stays for kyphoplasty.
Conducts independent compliance program assessments for various healthcare providers, investors, and lenders in connection with a large, national investor-owned hospital chain, national home health agency chain, behavioral health companies, several large and midsized hospice organizations, and multiple retail and specialty pharmacy companies.
Represented a national PBM organization in connection with a first of its kind CIA and resolution of a government investigation.
Secured summary judgment dismissal of a major FCA lawsuit, following intervention by the DOJ, for a durable medical equipment supplier of wound care mattress overlays after extensive discovery. The decision was upheld on appeal to the US Court of Appeals for the Fifth Circuit. (US ex rel. Carter v. Medica-Rents).
Defending physicians and other individuals, including healthcare executives, on OIG exclusion matters, including before ALJs and in federal district court.
Duke University School of Law, J.D.
Tufts University, B.A., magna cum laude
District of Columbia
Awards and Affiliations
Named, Modern Healthcare’s “Largest Healthcare Firm” (2016–2021)
Recommended, Industry Focus - Healthcare - Health Insurers, Service Providers, The Legal 500 US (2016-2022)
Ranked, Healthcare: Regulatory & Litigation, Nationwide, Chambers USA (2018, 2019)
Band 1, Healthcare, District of Columbia, Chambers USA (2020–2022)
Ranked, Healthcare, District of Columbia, Chambers USA (2018, 2019)
Ranked, Chambers USA: America's Leading Lawyers for Business (2006–2017)
Recognized, Washington DC Super Lawyers (2012–2018)